Brixmor (NYSE: BRX) is a real estate investment trust (REIT) that owns and operates a high-quality, national portfolio of open-air shopping centers. Its 363 retail centers comprise approximately 64 million square feet of prime retail space in established trade areas. The Company strives to own and operate shopping centers that reflect Brixmor's vision "to be the center of the communities we serve" and are home to a diverse mix of thriving national, regional and local retailers. Brixmor is a proud real estate partner to over 5,000 retailers including The TJX Companies, The Kroger Co., Publix Super Markets and Ross Stores.

Brixmor Property Group Inc.

Insiders have been trading these 5 stocks: (($IBRX)), (($KEYS)), (($RBRK)), (($AFL)) and (($MCO)). Here is a breakdown of their recent trades and t...

ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up

Belararox Ltd. ( ($AU:BRX) ) has issued an announcement. Belararox Ltd has relocated its corporate office, with its principal place of business now...

Belararox Relocates Corporate Office Without Changing Contact Details

Executive Accountability: Patrick Soon-Shiong Named in Securities Action NEW YORK, March 31, 2026 — Levi & Korsinsky, LLP notifies investors that D...

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky

ImmunityBio (IBRX) is facing a securities lawsuit after investors alleged that public statements about Anktiva overstated its capabilities, includi...

ImmunityBio Faces Securities Lawsuit Over Alleged Misleading Statements About Cancer Drug Anktiva

Belararox Ltd. ( ($AU:BRX) ) has provided an announcement. Belararox Ltd, a mineral explorer targeting copper, gold, silver, and zinc for technolog...

Belararox to Release 4.8 Million Escrowed Shares as Global Exploration Portfolio Advances

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Moleculin Biotech (MBRX) and Achieve Life Sciences (...

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (MBRX) and Achieve Life Sciences (ACHV)

ImmunityBio ($IBRX) shares dropped over 26% on Tuesday after the U.S. Food and Drug Administration (FDA) issued a warning letter to the biotechnolo...

“FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26%

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lineage Therap (LCTX) and Moleculin Biotech (MBRX) w...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Real Estate sector as 2 analysts just weighed in on G City Ltd (GZTGF) and Brixmor Property (BRX) with ...

Wall Street Analysts Are Bullish on Top Real Estate Picks

Belararox Ltd. ( ($AU:BRX) ) has provided an update. Belararox Limited has issued 2,500,000 fully paid ordinary shares following the vesting and co...

Belararox Issues 2.5 Million New Shares via Performance Rights Conversion

Belararox Ltd. ( ($AU:BRX) ) just unveiled an update. Belararox Ltd. has applied to the ASX for quotation of 2,500,000 new ordinary fully paid shar...

Belararox Seeks ASX Quotation for 2.5 Million New Shares

Moleculin Biotech ( ($MBRX) ) just unveiled an update. On March 19, 2026, Moleculin Biotech, Inc. reported that it is using a new corporate present...

Moleculin Biotech Updates Investors with New Corporate Presentation

Belararox Ltd. ( ($AU:BRX) ) just unveiled an announcement. Belararox Ltd. has released its condensed financial report for the half-year ended 31 D...

Belararox Issues Interim Financial Report for Half-Year to 31 December 2025

Belararox Ltd. ( ($AU:BRX) ) just unveiled an announcement. Belararox has acquired the El Faro tenement adjacent to its Toro South copper target wi...

Belararox Expands Toro South Footprint With El Faro Tenement Acquisition

LB Pharmaceuticals, Inc. ( ($LBRX) ) has issued an update. On March 6, 2026, LB Pharmaceuticals appointed veteran neuroscience drug development exe...

Current Quarter	$0.57	Next Quarter	$0.59
Current Year	$2.35	Next Year	$2.47
QoQ Growth	+3.5%	YoY Growth	+5.1%
3Y EPS CAGR	+7.2%	Target Price	$32.21
Consensus	Buy	Upside	+11.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BRX	$28.90	0.00%	2.77M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BRX	$28.90	0%	2.77M
3
4
5
6

BRX

BRX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Brixmor Property Group Inc. Data in Excel

Get Brixmor Property Group Inc. Data in Excel